Steven Treon, MD, PhD, Dana-Farber Cancer Institute, Boston, MA, discusses the retrospective, multicenter study of ibrutinib for the treatment of Bing-Neel syndrome. This syndrome is becoming more common as people live longer with Waldenström’s macroglobulinemia. This interview took place at the 15th International Conference on Malignant Lymphoma (ICML), in Lugano, Switzerland.